How UltraSight used data-driven strategy to identify the right markets and accelerate investor confidence
UltraSight is a digital health leader leveraging machine learning to transform cardiac imaging workflows. The company’s AI-driven software delivers real-time guidance and quality assessment, enabling medical professionals regardless of sonography experience to capture accurate, high-quality cardiac ultrasound images. By making imaging more accessible across clinics, community hospitals, ambulances, and even remote or rural locations, UltraSight empowers clinicians to confidently provide timely, quality cardiac care anywhere.
TO SUPPORT ITS DATA-DRIVEN COMMERCIALIZATION STRATEGY, ULTRASIGHT LEVERAGED DEFINITIVE HEALTHCARE’S ANALYTICS TO:
- Validate market opportunity
- Map patient pathways
- Enrich field insights for targeted go-to-market execution
Empowering clinicians to make better decisions
In acute care, clinicians often face high-stakes choices: should they discharge the patient with follow-up, admit for further care, or place them under observation? Traditional workflows, fragmented by delays and limited access to expertise, can slow these decisions and risk missed opportunities for timely treatment. At the same time, demand for echocardiographic monitoring continues to rise, while patients outside major medical centers struggle with limited access. UltraSight’s software closes these gaps by providing immediate, actionable imaging data. With real-time guidance at the point of care, clinicians can make confident triage decisions that improve outcomes for patients and protect health system revenue.
The challenge
While the need for timely cardiac imaging is acute, hospital systems are fragmented, shift-driven, and challenged by high staff turnover. UltraSight’s commercial team sought to quantify the market opportunity and validate the scalability of its model using credible, third-party data. The goal was to strengthen an investor narrative already grounded in clinical and operational insights.
Specifically, UltraSight sought to:
- Understand which patients could benefit from UltraSight’s technology
- Map patient pathways to identify leakage and revenue opportunities
- Validate market potential with credible data for investors and partners
The solution
Data driven insights to quantify opportunity and optimize operations
UltraSight designed a market validation framework and used Definitive Healthcare data to build a total addressable market model that went beyond raw numbers. The report quantified patient volumes across ten CCS codes and mapped care pathways, showing who received echocardiograms in the inpatient setting, within two weeks, or not at all. This revealed gaps in timeliness, missed revenue, and opportunities for improving patient flow without overburdening staff.
Combining field feedback with Definitive Healthcare data, UltraSight identified higher value use cases and strategically refocused on outpatient echo labs — a shift driven by its own operational and commercial insights. Echo labs are often overwhelmed with non-billable inpatient work, while outpatient referrals face delays of several weeks. Redirecting sonographer capacity toward billable outpatient and higher complexity echoes offers a way to relieve operational pressure, drive timely patient care and create new revenue streams.
By combining data with real-world insights, UltraSight sharpened its focus and built a compelling investor narrative: reducing the cost of a hospital stay (rather than its duration) and unlocking scalable, billable outpatient echo capacity.
The impact
Insights used to tell a winning investor story
Insights from Definitive Healthcare data have reinforced UltraSight’s broader commercialization strategy — one built on clinical validation, operational impact, and data-driven decision-making. By focusing on where clinical need is high, adoption is practical, and revenue impact is measurable, the company has positioned itself for sustainable growth, through the following:
Clear investor narrative: UltraSight quantified and validated its market opportunity using Definitive Healthcare data to substantiate the size and impact of its solution.
Field enablement: Account-specific insights will allow a 20-person field team to tailor conversations to each customer’s echo lab environment and pain points.
As Ramya Singh, UltraSight’s Chief Commercial Officer, notes, the power lies not just in data access but in how UltraSight translates insights into strategy.
We began with a strong hypothesis about where our technology could drive efficiency and revenue impact. Definitive’s data helped us validate that with confidence.